Dr Diakos’ research is focused on finding markers to help guide treatment and predict disease course and treatment response. Her main focus is on bowel, breast and gynaecological cancers and encourages all of her patients to become involved in studies and trials. It’s through research that we are able to effect significant changes to patients’ lives. Dr Diakos is an active member of the cooperative trials groups AGITG, ANZGOG, BCT.
MOGA, COSA, AGITG, ANZGOG, ESMO, ASCO, BCT, ENETS.
Publications and affiliations
- Cancer-related inflammation and treatment effectiveness. C.I. Diakos, K.A. Charles, D.C. McMillan, S.J. Clarke. Lancet Oncology 2014; 15: e493-503.
- A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. F. Vafaee, C.I. Diakos, M.B. Kirschner, G. Reid, M. Michael, L.G. Horvath, Z.J. Cheng, Z. Kuncic, S.J. Clarke. npj Systems Biology and Applications 2018 4(1), 20.
- The lymphocyte-to-monocyte ratio is a superior predictor of survival in comparison to established biomarkers of resectable colorectal cancer. J.C.Y. Chan, D.L. Chan, C.I. Diakos, A. Engel, N. Pavlakis, A. Gill, S.J. Clarke. Annals of Surgery 2017; 265(3), 539-546.
- Tumour sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. J.C.Y. Chan, C.I. Diakos, D.L. Chan, A. Engel, A. Gill, S.J. Clarke; PLOS One; 2019 14(6), e0218207.
- A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial re-measurement. J.C.Y. Chan, C.I. Diakos, D.L. Chan, A. Engel, N. Pavlakis, A. Gill, S.J. Clarke. Annals of Surgery 2018; 267(6): 1119-1125.